Health-care companies ticked down as traders rotated into more rate-sensitive areas.
Eli Lilly will spend $5.3 billion to boost manufacturing capacity for its hot-selling anti-obesity drug Zepbound and affiliated diabetes drug Mounjaro, a huge investment to ease shortages of the popular drugs.
Novo Nordisk rose after the Danish obesity-drug giant said its Ozempic injection showed promise in a trial on patients with kidney conditions.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
05-24-24 1725ET
